T Cell Directed Therapy in Prostate Cancer: Live Session From The Uromigos Live & Unplugged 2024

By Brian Rini, MD, FASCO, Michael Morris, MD, Tanya Dorff, MD, Karen Autio, MD - Last Updated: October 2, 2024

Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024, recorded live in Nashville! Chair Brian Rini, MD, is joined by Michael Morris, MD; Tanya Dorff, MD; and Karen Autio, MD, for a discussion on T cell directed therapy for prostate cancer.

Click the image below to access the slide PDFs.

Post Tags:Uromigos Live 2024: Focus on Prostate Cancer

Co-PSMA Trial: Head-to-Head Comparison of 64Cu-SAR-bis-PSMA vs 68Ga-PSMA-11

Louise Emmett, MDProstate Cancer Diagnostics | March 24, 2025

Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...

Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT

Phouc T. Tran, MD, PhDProstate Cancer | March 18, 2025

Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.

Patient Perceptions of Germline Genetic Testing Benefits for Prostate Cancer

Emily MenendezProstate Cancer Diagnostics | March 13, 2025

Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.

ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC

Emily MenendezRLT | March 7, 2025

Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.

TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing

Alan Tan, MDCRPC | March 5, 2025

Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.

T Cell Directed Therapy in Prostate Cancer: Live Session From The Uromigos Live & Unplugged 2024

Related Posts